ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,420.26
-0.22%
Dow Jones
40,003.59
0.34%
Gold vs US Dollar
2,413.935
0.00%
Brent Oil
83.76
0.00%
Bitcoin
67,321.12
0.57%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE

  6. Novartis AG (NVS) Share Price

NVS Novartis AG

102.57
-0.12 (-0.12%)
18 May 2024 - Closed
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 Novartis AG NYSE:NVS New York Stock Exchange Depository Receipt  ADR
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   -0.12 -0.12 102.57 0.00 0.00 102.93 102.50 102.87 781,508 00:00:00   
*quotes are delayed by at least 20 minutes
 Sector  Turnover  Profit  EPS - Basic  PE ratio  Mkt Cap 
 Pharmaceutical Preparations 54.11B 14.85B 7.2670 14.06 208.78B
 Type  Size  Price  Time  Units 
 13 110,056 102.57 23:00:00 USD
 
Pre-Market and After-Hours
Recent News
DateTimeSource
HeadlineMore NVS News
07/05/202412:00GLOBEArvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
23/04/202412:25IHMARKETNEWSApple Loses Market Share in China, GM Surges in Pre-Market Following Upward Revisions for 2024 Projections, and More News
15/04/202419:00PRNUSNew Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
11/04/202412:00GLOBEArvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
10/04/202412:13IHMARKETNEWSDelta Generates US$37 Million Profit in Q1, Google and Intel Unveil Cutting-Edge AI Chips, and More News
06/04/202421:16PRNUSNew Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting
15/02/202421:15EDGAR2Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
Period
Draw mode
Latest Message Board Discussions
DateTimeSource
Title
Posts
13/08/201221:17PBBNortherners Vs Southerners: Whos "best"123
Data Downloads for NVS

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest Novartis AG Articles